We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study.
- Authors
Martenson, James A.; Lipsitz, Stuart R.; Lefkopoulou, Myrto; Engstrom, Paul F.; Dayal, Yogeshwar Y.; Cobau, Charles D.; Oken, Martin M.; Hatter, Daniel G.; Martenson, J A; Lipsitz, S R; Lefkopoulou, M; Engstrom, P F; Dayal, Y Y; Cobau, C D; Oken, M M; Haller, D G
- Abstract
<bold>Background: </bold>This prospective study assessed combined modality therapy of patients with International Union Against Cancer classification T1-4 N0 M0 anal cancer.<bold>Methods: </bold>Protocol therapy consisted of a dose of 4000 cGy to the pelvis, anus, and perineum, followed by a 1000-1300 cGy boost. Infusions of 5-fluorouracil and mitomycin-C were administered when radiation therapy began. A second infusion of 5-fluorouracil was administered 28 days later. Biopsy was performed 6-8 weeks after completion of treatment. Positive biopsy findings resulted in abdominal-perineal resection.<bold>Results: </bold>Survival at 7 years for 50 eligible patients was 58%. White patients and those with favorable performance status had significantly better survival. Of the 46 patients evaluable for response, 34 had a complete response, 11 had a partial response, and 1 had no response. Seven-year survival for partial responders was 53%. Freedom from locoregional progression was 80% at 7 years.<bold>Conclusion: </bold>Treatment with a combination of chemotherapy and radiation therapy is effective for patients with anal cancer. The investigation of methods of improving therapy is warranted.
- Publication
Cancer (0008543X), 1995, Vol 76, Issue 10, p1731
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19951115)76:10<1731::AID-CNCR2820761009>3.0.CO;2-H